| Chen, Jie |
NCT05830500: Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma |
|
|
| Recruiting | 4 | 360 | RoW | Anlotinib Hydrochloride Capsule | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Medullary Thyroid Cancer | 06/27 | 12/28 | | |
| Active, not recruiting | 3 | 291 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib | Loxo Oncology, Inc., Eli Lilly and Company | Medullary Thyroid Cancer | 05/23 | 02/26 | | |
COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin) | ITM Solucin GmbH | Neuroendocrine Tumors | 06/27 | 09/27 | | |
NCT06616532: PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 404 | RoW | PM8002, Paclitaxel, Topotecan | Biotheus Inc. | SCLC | 01/27 | 12/28 | | |
| Recruiting | 3 | 120 | Europe, Canada, Japan, US, RoW | Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002 | Takeda, Takeda Development Center Americas, Inc. | Crohn's Disease (CD) | 11/24 | 11/24 | | |
| Active, not recruiting | 3 | 121 | Europe, Canada, Japan, US, RoW | Vedolizumab, MLN0002, ENTYVIO, KYNTELES | Takeda, Takeda Development Center Americas, Inc. | Colitis, Ulcerative | 08/25 | 08/25 | | |
| Recruiting | 3 | 240 | Europe, Canada, Japan, US, RoW | Vedolizumab IV, MLN0002, ENTYVIO, KYNTELES, No Intervention | Takeda, Takeda Development Center Americas, Inc. | Ulcerative Colitis, Crohn's Disease | 08/31 | 08/31 | | |
NCT06398444: A Clinical Study to Evaluate the Safety and Efficacy of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms |
|
|
| Not yet recruiting | 2/3 | 74 | RoW | Lutetium[177Lu] Oxodotreotide Injection | Sinotau Pharmaceutical Group | Advanced Neuroendocrine Neoplasm | 06/27 | 06/29 | | |
NCT05033132: A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer |
|
|
| Withdrawn | 2 | 177 | RoW | Balstilimab, Balstilimab + Zalifrelimab | Agenus Inc., Betta Pharmaceuticals Co., Ltd. | Cervical Cancer | 12/24 | 12/24 | | |
NCT04893759: A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors |
|
|
| Recruiting | 1 | 60 | RoW | Pelcitoclax, APG-1252 | Ascentage Pharma Group Inc. | Neuroendocrine Tumors | 06/24 | 06/25 | | |
| Active, not recruiting | N/A | 51 | RoW | MitraClip procedure | Abbott Medical Devices | Mitral Regurgitation | 05/24 | 05/25 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
